Lexeo Therapeutics (NASDAQ:LXEO) CFO Louis Edward Tamayo Sells 4,117 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,117 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $4.91, for a total transaction of $20,214.47. Following the transaction, the chief financial officer owned 92,907 shares in the company, valued at $456,173.37. This represents a 4.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Louis Edward Tamayo also recently made the following trade(s):

• On Wednesday, July 1st, Louis Edward Tamayo sold 4,641 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.49, for a total transaction of $20,838.09.

Lexeo Therapeutics Stock Performance

LXEO stock opened at $5.37 on Thursday. The business’s 50-day moving average is $4.70 and its two-hundred day moving average is $5.56. The company has a market cap of $440.61 million, a price-to-earnings ratio of -4.67 and a beta of 1.46. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Equities analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its position in Lexeo Therapeutics by 370.0% during the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock valued at $175,000 after acquiring an additional 39,627 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Lexeo Therapeutics by 654.8% in the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock valued at $3,718,000 after purchasing an additional 929,538 shares during the period. Acadian Asset Management LLC purchased a new position in Lexeo Therapeutics in the first quarter valued at $85,000. Rhumbline Advisers raised its position in shares of Lexeo Therapeutics by 19.8% in the first quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after acquiring an additional 4,995 shares during the period. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LXEO shares. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Wall Street Zen lowered shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. decreased their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.